Home
Conditions
Hemostatic Disorders

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,075 public trials 581 recruiting studies

Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Completed

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

NCT00499811

Conditions: Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, +112 more
Locations: City of Hope Medical Center Duarte, California, United States

University of Southern California Los Angeles, California, United States

Emory University/Winship Cancer Institute Atlanta, Georgia, United States

National Institutes of Health Bethesda, Maryland, United States

View Trial Details

Completed

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

NCT00458731

Conditions: Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, +116 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

NCT00665314

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +18 more
Locations: Berlin, Germany

Cologne, Germany

Dresden, Germany

Nuremberg, Germany

View Trial Details

Completed

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

NCT00950911

Conditions: Blood Protein Disorders, Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, +28 more
Locations: Research Site Jindřichův Hradec, Czechia

Research Site Kroměříž, Czechia

Research Site Olomouc, Czechia

Research Site Prague, Czechia

View all 17 locations

View Trial Details

Completed

A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma

NCT00725634

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: Investigational Site 2 Scottsdale, Arizona, United States

Investigational Site 3 Columbus, Ohio, United States

Investigational Site 1 San Antonio, Texas, United States

View Trial Details

Completed

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

NCT00750815

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States

View Trial Details

Completed

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

NCT00617591

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States

View Trial Details

Completed

Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT00060203

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Ireland Cancer Center Cleveland, Ohio, United States

View Trial Details

Completed

VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

NCT00440765

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations: 's-Hertogenbosch, Netherlands

Alkmaar, Netherlands

Amersfoort, Netherlands

Amstelveen, Netherlands

View all 44 locations

View Trial Details

Completed

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

NCT00499577

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Greenebaum Cancer Center at University of Maryland Medical Center Baltimore, Maryland, United States

Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States

View Trial Details

Hemostatic Disorders

Hemostatic Disorders trial results

Related conditions